Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02662803
Other study ID # EA1/217/15
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 2015
Est. completion date January 2019

Study information

Verified date February 2019
Source Charite University, Berlin, Germany
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study investigate the effect of high-intense aerobe exercise training (HIT) on clinical and physiological parameters (anxiety, somatisation, cortisol, alpha amylase, "mismatch negativity", loudness dependence auditory evoked potentials) in patients with generalized anxiety disorder (GAD). Half of patients will receive HIT, while the other half will receive aerobe exercise of low intensity.


Description:

Generalized anxiety disorder (GAD) is a prevalent psychiatric condition and characterized by worrying of several topics of the daily life as well as stress-induced somatic symptoms (e.g. headache or musculoskeletal pain). Disturbed monoaminergic neurotransmission, changes in central information processing and altered levels of stress markers were reported as to be biological correlates of GAD or other stress-related disorders. Cognitive behavioral therapy is the first-line treatment in GAD, but it seems to be less effective than in other anxiety disorders. There is, however, some evidence for an anxiolytic activity of aerobe exercise. In this context, different forms of aerobe training were found to be associated with significant reduction of clinical symptoms in panic disorder, agoraphobia or social phobia as well as a normalisation of some of its pathophysiological markers.

In this study, 20 patients with GAD will receive a high-intensive aerobe training (HIT, 6 HIT-sessions of 20 minutes within a period of 12 days). Additionally, 20 GAD-patients will undergo a less intense aerobe training matched regarding frequency and duration of sessions. Prior to the first training session, after completing the training (day 12) and 30 days after baseline, symptoms of anxiety and somatisation will assessed by using established questionnaires. Moreover, saliva samples and electroencephalogram (EEG) will performed at the same times of assessment in order to evaluating changes of cortisol, alpha amylase, "mismatch negativity" and loudness dependence auditory evoked potentials.

We hypothesize, that GAD-patients which undergo HIT, will show a stronger and more sustained improvement of both, clinical symptoms and formally altered electrophysiological and endocrinological parameters.


Recruitment information / eligibility

Status Completed
Enrollment 29
Est. completion date January 2019
Est. primary completion date January 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Generalized Anxiety Disorder (GAD) according to the 5th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5)

- Appropriate abilities to communicate and to complete the questionnaires

- Written informed consent

- Possibility of regular attendance at the training sessions

Exclusion Criteria:

- Other severe mental conditions than GAD (e.g. schizophrenia, severe depressive episode, addiction)

- Acute suicidality

- Epilepsy or other disorders of the central nervous system (e.g. tumor, encephalitis)

- Contraindications to aerobe exercise training

- Cardiovascular diseases

- Start or modification of an anxiolytic pharmacotherapy within the last four weeks

- Current psychotherapy

Study Design


Related Conditions & MeSH terms


Intervention

Other:
high-intensive aerobe exercise
Aerobe bicycle ergometer training within 77-95% of maximum oxygen consumption; duration of each training session: 20 minutes; frequency of training: 6 sessions within 12 days
low-intensive aerobe exercise
Aerobe training below 70% of maximum oxygen consumption (including light stretching and simple exercises adapted from yoga figures); duration of training session: 20 minutes; frequency of training: 6 sessions within 12 days

Locations

Country Name City State
Germany Department of Psychiatry and Psychotherapy, Charité - Universitätsmedizin Berlin, Campus Mitte Berlin

Sponsors (1)

Lead Sponsor Collaborator
Charite University, Berlin, Germany

Country where clinical trial is conducted

Germany, 

References & Publications (13)

Burgomaster KA, Hughes SC, Heigenhauser GJ, Bradwell SN, Gibala MJ. Six sessions of sprint interval training increases muscle oxidative potential and cycle endurance capacity in humans. J Appl Physiol (1985). 2005 Jun;98(6):1985-90. Epub 2005 Feb 10. — View Citation

Clark CR, McFarlane AC, Weber DL, Battersby M. Enlarged frontal P300 to stimulus change in panic disorder. Biol Psychiatry. 1996 May 15;39(10):845-56. — View Citation

Gaudlitz K, Plag J, Dimeo F, Ströhle A. Aerobic exercise training facilitates the effectiveness of cognitive behavioral therapy in panic disorder. Depress Anxiety. 2015 Mar;32(3):221-8. doi: 10.1002/da.22337. Epub 2014 Dec 17. — View Citation

Ghisolfi ES, Heldt E, Zanardo AP, Strimitzer IM Jr, Prokopiuk AS, Becker J, Cordioli AV, Manfro GG, Lara DR. P50 sensory gating in panic disorder. J Psychiatr Res. 2006 Sep;40(6):535-40. Epub 2006 Apr 17. — View Citation

Hegerl U, Juckel G. Intensity dependence of auditory evoked potentials as an indicator of central serotonergic neurotransmission: a new hypothesis. Biol Psychiatry. 1993 Feb 1;33(3):173-87. Review. — View Citation

Jayakody K, Gunadasa S, Hosker C. Exercise for anxiety disorders: systematic review. Br J Sports Med. 2014 Feb;48(3):187-96. doi: 10.1136/bjsports-2012-091287. Epub 2013 Jan 7. Review. — View Citation

Maier W, Buller R, Philipp M, Heuser I. The Hamilton Anxiety Scale: reliability, validity and sensitivity to change in anxiety and depressive disorders. J Affect Disord. 1988 Jan-Feb;14(1):61-8. — View Citation

Meyer TJ, Miller ML, Metzger RL, Borkovec TD. Development and validation of the Penn State Worry Questionnaire. Behav Res Ther. 1990;28(6):487-95. — View Citation

Näätänen R. The mismatch negativity: a powerful tool for cognitive neuroscience. Ear Hear. 1995 Feb;16(1):6-18. Review. — View Citation

Plag J, Gaudlitz K, Schumacher S, Dimeo F, Bobbert T, Kirschbaum C, Ströhle A. Effect of combined cognitive-behavioural therapy and endurance training on cortisol and salivary alpha-amylase in panic disorder. J Psychiatr Res. 2014 Nov;58:12-9. doi: 10.1016/j.jpsychires.2014.07.008. Epub 2014 Jul 21. — View Citation

Plag J, Schumacher S, Ströhle A. [Generalized anxiety disorder]. Nervenarzt. 2014 Sep;85(9):1185-94. doi: 10.1007/s00115-014-4121-8. German. — View Citation

Schumacher S, Kirschbaum C, Fydrich T, Ströhle A. Is salivary alpha-amylase an indicator of autonomic nervous system dysregulations in mental disorders?--a review of preliminary findings and the interactions with cortisol. Psychoneuroendocrinology. 2013 Jun;38(6):729-43. doi: 10.1016/j.psyneuen.2013.02.003. Epub 2013 Mar 5. Review. — View Citation

Stöber J, Bittencourt J. Weekly assessment of worry: an adaptation of the Penn State Worry Questionnaire for monitoring changes during treatment. Behav Res Ther. 1998 Jun;36(6):645-56. — View Citation

* Note: There are 13 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Penn State Worry Questionnaire (PSWQ, german version) PSWQ is a questionnaire for detecting the severity of GAD From baseline to post therapy (+12 days) and from baseline to follow-up (+30 days)
Secondary Change in Screening für somatoforme Störungen (SOMS) SOMS is a questionnaire for detecting the severity of somatisation From baseline to post therapy (+12 days) and from baseline to follow-up (+30 days)
Secondary Change in Penn State Worry Questionnaire-past week (PSWQ-PW, german version) PSWQ-PW is a questionnaire for detecting changes in GAD-severity From baseline to post therapy (+12 days) and from baseline to follow-up (+30 days)
Secondary Change in Screening für somatoforme Störungen - 7 Tage (SOMS-7T) SOMS-7T is a questionnaire for detecting changes in somatisation From baseline to post therapy (+12 days) and from baseline to follow-up (+30 days)
Secondary Change in Hamilton Anxiety Rating Scale (HAM-A, german version) HAM-A is a questionnaire for detecting the severity and changes of anxiety From baseline to post therapy (+12 days) and from baseline to follow-up (+30 days)
Secondary Change in Anxiety Control Questionnaire (ACQ, german version) ACQ is a questionnaire for evaluating the ability to control anxiety From baseline to post therapy (+12 days) and from baseline to follow-up (+30 days)
Secondary Change in saliva cortisol Cortisol is an established marker of the psychophysiological stress response From baseline to post therapy (+12 days) and from baseline to follow-up (+30 days)
Secondary Change in saliva alpha amylase Alpha amylase is an established marker of the psychophysiological stress response From baseline to post therapy (+12 days) and from baseline to follow-up (+30 days)
Secondary Change in mismatch negativity Mismatch negativity is an established correlate of the central information processing From baseline to post therapy (+12 days) and from baseline to follow-up (+30 days)
Secondary Change in loudness dependence auditory evoked potentials Loudness dependence auditory evoked potentials are established correlates of the central serotonergic transmission From baseline to post therapy (+12 days) and from baseline to follow-up (+30 days)
See also
  Status Clinical Trial Phase
Completed NCT01470469 - SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP) Phase 2
Completed NCT02305797 - EDG004 Treatment of Adult Patients With Generalized Anxiety Disorder (GAD) Phase 3
Active, not recruiting NCT05738850 - Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the Body of Healthy Adult Participants Phase 1
Recruiting NCT06024239 - A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD) Phase 1
Withdrawn NCT02708472 - Safety and Efficacy of Synchronized Transcranial Magnetic Stimulation for the Treatment of Generalized Anxiety Disorder N/A